Press "Enter" to skip to content

FDA Eyes Jardiance for HFrEF; 60% of Americans Obese in 2030?

The FDA will review empagliflozin (Jardiance) as a potential treatment to reduce the risk of cardiovascular death and hospitalization for heart failure and to slow kidney function decline in adults with chronic heart failure with reduced ejection fraction with and without type 2 diabetes, based on the phase III EMPEROR-Reduced trial, Boehringer Ingelheim and Eli Lilly announced.

In other FDA news, the agency also granted 510(k) clearance to Quanta Dialysis Technologies’ portable SC+ Hemodialysis System.

Just 6 months of adherence to a strict low-carb diet could help to put type 2 diabetes in remission. (The BMJ)

The Endocrine Society updated its position statement on insulin access and affordability, saying policymakers should do more to lower out-of-pocket insulin costs. (Journal of Clinical Endocrinology & Metabolism)

New data from the American Obesity Association predicts that half of Americans will have obesity by 2025 and 60% will have obesity by 2030.

According to CDC data from 2015-2018, the average American man stood 5’9″ and weighed around 200 lbs, while the average woman stood 5’3.5″ and weighed in at 171 lbs.

In a survey of 1,010 adults, 65% said they would be willing to adopt remote digital monitoring modalities for managing their diabetes — even if it only modestly improved their health. (JAMA Network Open)

In a phase II study, the osteoporosis drug denosumab (Prolia) helped prevent osteoclasts from forming after total hip arthroplasty surgery. (The Lancet Rheumatology)

  • Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry, and dermatology news. Based out of the New York City office, she’s worked at the company for nearly five years.